{'fraction_non_alphanumeric': 0.03225806451612903, 'fraction_numerical': 0.016129032258064516, 'mean_word_length': 5.669421487603306, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
ADGRF1 signaling pathways in Breast Cancer

Adhesion G‐protein‐coupled receptors (GPCRs) form the second largest GPCR subfamily. They control many cellular processes involved in cancer, such as cell adhesion, invasion/migration, and stem cell function. Most of adhesion GPCRs are still orphans without any known endogenous ligands. In breast cancer, ADGRF1, previously called GPR110, is overexpressed in 2 aggressive subtypes of breast cancers, HER2+ and triple‐negative. We have found that HER2+ cells with ADGRF1 overexpression in doxycycline‐inducible manner formed more secondary mammospheres and more colonies in the soft agar assay and had higher % of Aldefluor+ cell population. However, ADGRF1‐overexpressing BT474 cells formed fewer tumors in mice and had reduced tumor growth compared to control.